Moderna And Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna’smRNA Respiratory Vaccine Portfolio in Japan, Including COVID-19 Vaccines
CAMBRIDGE, MA and OSAKA, JAPAN / July 8, 2024-- Moderna, Inc. (Nasdaq: MRNA) and Mitsubishi
Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement
regarding the co-promotion of Moderna’s mRNA respiratory vaccine portfolio in Japan, including
Moderna’s COVID-19 vaccine, Spikevax®.
Under the agreement, Moderna will handle the manufacturing, sales, medical education anddistribution of its mRNA respiratory vaccines. Both companies will engage in activities to enable broad
access to Moderna’s mRNA respiratory portfolio to have the maximum impact on public health in Japan.
The agreement has an initial term until March 31, 2029 and no further details on the financial terms ofthe deal are being disclosed.
"We are pleased to partner with Mitsubishi Tanabe Pharma to enable the commercialization of our
COVID-19 vaccine and future mRNA respiratory vaccine portfolio to the people of Japan,” said Kazumasa
Nagayama, President and Representative Director of Moderna Japan. “Mitsubishi Tanabe Pharma has asignificant heritage in Japan and has long contributed to public health through numerous vaccines andpossesses extensive experience and deep knowledge in this area. We look forward to working together
to provide our COVID-19 vaccine in Japan, given the virus continues to pose a significant threat to publichealth.”
Akihiro Tsujimura, Representative Director of Mitsubishi Tanabe Pharma, said, “Moderna has delivered
COVID-19 vaccines to many people worldwide since the COVID-19 pandemic began. We are delighted tocollaborate with Moderna and engage in commercial activities for the COVID-19 vaccine and othermRNA respiratory vaccines in Japan. We will continue to contribute to public health in Japan throughour vaccine business.”
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA
technology, Moderna is reimagining how medicines are made and transforming how we treat andprevent disease for everyone. By working at the intersection of science, technology and health for morethan a decade, the company has developed medicines at unprecedented speed and efficiency, including
one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious
diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global
team driven by the Moderna values and mindsets to responsibly change the future of human health,Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more
information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter),
Facebook, Instagram, YouTube and LinkedIn.
About Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), isone of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethicalpharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s
pharmaceutical industry. MCG has positioned health care as its strategic focus in its management policy,“Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC1

is working on the disease areas of central nervous system, immuno-inflammation, diabetes and kidney,and cancer. MTPC is focusing on “precision medicine” to provide drugs with high treatment satisfaction
by identifying patient populations with high potential for efficacy and safety. In addition, MTPC isworking to develop “around the pill solutions” to address specific patient concerns based on therapeuticmedicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravationand prognosis. For more information, go to https://www.mt-pharma.co.jp/e/Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended, including statements regarding: Moderna Japan andMitsubishi Tanabe Pharma Corporation entering into a joint agreement regarding the co-promotion ofModerna’s mRNA respiratory vaccine portfolio in Japan and the terms of that agreement. The forwardlooking statements in this press release are neither promises nor guarantees, and you should not place
undue reliance on these forward-looking statements because they involve known and unknown risks,
uncertainties, and other factors, many of which are beyond Moderna's control and which could cause
actual results to differ materially from those expressed or implied by these forward-looking statements.
These risks, uncertainties, and other factors include, among others, those risks and uncertainties
described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year
ended December 31, 2023, and in subsequent filings made by Moderna with the U.S. Securities andExchange Commission, which are available on the SEC's website at www.sec.gov. Except as required bylaw, Moderna disclaims any intention or responsibility for updating or revising any forward-looking
statements contained in this press release in the event of new information, future developments orotherwise. These forward-looking statements are based on Moderna's current expectations and speak
only as of the date of this press release.
Moderna Contacts
Media:
International media
Luke Mircea-Willats
Senior Director, International Communications
Luke.mirceawillats@modernatx.com
Moderna Japan
Communications & Media
japan-pr@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
Mitsubishi Tanabe Pharma Contacts
Media:PR Group PR Department, Pharma Business Strategy Division+81-6-6205-5119
2

Source: Moderna, Inc.

3